Originally published on the YC Blog on April 29, 2019. By Jared Friedman In the last 10 years, the tools for studying biology have become much less expensive and more widely available. This has made it possible for new startups to do serious research right from the start, and it is leading to an explosion […]
Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform WILMINGTON, Mass., and SAN FRANCISCO, Calif., January 11, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, […]
Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery. SAN FRANCISCO, January 11, 2019 – Atomwise, Inc. today announced a strategic alliance with Charles River Laboratories International, Inc., which will offer biotech and pharmaceutical companies an end-to-end drug discovery solution that unites AI […]
Atomwise Inc., a leader in Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer Inc. (NYSE: PFE). Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer. In the agreement, Pfizer will pay a technology access fee and additional […]